Author

K. Sachaphibulkij

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

L. H. K. Lim· 3 shared R. Jakhar· 2 shared A. D. Jeyasekharan· 1 shared A. K. Gao· 1 shared A. Shendre· 1 shared B. Halliwell· 1 shared B. V. Au· 1 shared B. W. Q. Tan· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

L. H. K. Lim

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Tumour-derived extracellular vesicles within the therapy-induced senescent secretome distinctly suppress breast cancer via DKK1-mediated inflammatory response.

M. Robert, R. Jakhar, B. V. Au, G. W. L. Eng, M. Wei, A. K. Gao, Y. H. Chuah, K. Sachaphibulkij, I. Bonne, K. J. Lim, I. Sinha, D. B. L. Teh, L. H. K. Lim, P. Kumar, N. K. Verma, , K. C. Crasta

This study identifies that TIS-derived extracellular vesicles suppress breast cancer through DKK1-mediated inflammation, contrasting with the pro-tumorigenic effects of the senescence-associated secretome.

bioRxiv · Mar 29, 2024 · PreprintCancer Biology

Protection against doxorubicin-induced cardiotoxicity by ergothioneine

I. K. Cheah, R. M. Y. Tang, X. Wang, K. Sachaphibulkij, S. Y. Chong, L. H. K. Lim, J.-W. Wang, B. Halliwell

This study investigates ergothioneine's protective effects against doxorubicin-induced cardiotoxicity in mice and finds it significantly reduces cardiac dysfunction without affecting tumor growth or chemotherapy efficacy.

bioRxiv · Dec 21, 2022Physiology

PLK1 inhibition selectively kills ARID1A deficient cells through uncoupling of oxygen consumption from ATP production

U. S. Srinivas, G. K. Ramachandran, J. D. Wardyn, M. M. Hoppe, Y. Peng, S. Lim, M. Y. Lee, P. C. Peethala, O. An, A. Shendre, B. W. Q. Tan, T. S. C. Norbert, P. Jaynes, L. Hu, R. Jakhar, , A. D. Jeyasekharan

This study identifies ARID1A deficiency as a biomarker for PLK1 inhibitor sensitivity by revealing a mitochondrial metabolic vulnerability in these cells.

bioRxiv · Jun 1, 2021 · PreprintCancer Biology